1RT.F NUFORMIX PLC LS -001

Healthcare Biotechnology Frankfurt Exchange
0.0010 EUR
Close of Nov 11, 2026
0.0005 0.0050
Market cap
EUR 2.61M
P/E
-
P/B
1.33x
ROE
-86.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Mar 2025.

Is 1RT.F undervalued?

Graham number

The Graham number of NUFORMIX PLC LS -001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NUFORMIX PLC LS -001 fundamental analysis

No fundamental analysis for NUFORMIX PLC LS -001 yet.

NUFORMIX PLC LS -001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NUFORMIX PLC LS -001

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for …

Full company profile